Related Experiment Videos
[Disorders of sphingolipid activator proteins]
1Tokyo Metropolitan Institute of Medical Science.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 1, 1995
Summary
Small-molecular nonenzymatic glycoproteins, like GM2 activator and prosaposin, are crucial for sphingolipid degradation in lysosomes. Mutations in their genes cause rare genetic disorders, offering insights into lysosomal storage diseases.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Context:
- Lysosomes degrade sphingolipids via nonenzymatic glycoproteins.
- GM2 activator (chromosome 5) and prosaposin (chromosome 10) are key activator proteins.
- These proteins are essential for the hydrolysis of specific gangliosides.
Purpose:
- To elucidate the roles of GM2 activator and prosaposin family proteins in lysosomal sphingolipid metabolism.
- To investigate the molecular mechanisms underlying GM2-gangliosidosis AB variant, prosaposin deficiency, and saposin C deficiency.
Summary:
- GM2 activator is vital for ganglioside GM2 hydrolysis; its gene mutations lead to GM2-gangliosidosis AB variant.
- Prosaposin is processed into saposins A, B, C, and D, each with distinct functions.
- Mutations in prosaposin or saposin C cause diseases resembling Gaucher disease types 2 and 3, respectively.
Impact:
- These rare genetic disorders provide critical insights into enzyme-substrate interactions within lysosomes.
- Understanding these pathways can inform therapeutic strategies for lysosomal storage diseases.
- Highlights the importance of nonenzymatic glycoproteins in maintaining cellular homeostasis and preventing lipid accumulation.